SCHEMBL5782151

SCHEMBL5782151

CCOC(=O)C1C(=O)c2ccncc2C1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.47
KDM4E B2RXH2 4/20 0.47
ALDH1A1 P00352 3/20 0.47
CASP1 P29466 1/20 0.47
CASP7 P55210 1/20 0.47
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
GAA P10253 2/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
KDM5A P29375 1/20 0.39
KDM5B Q9UGL1 1/20 0.39
TDP2 O95551 1/20 0.39
MMP13 P45452 1/20 0.38
CCNC P24863 1/20 0.37
CDK8 P49336 1/20 0.37
CDC7 O00311 1/20 0.37
DBF4 Q9UBU7 1/20 0.37
NPSR1 Q6W5P4 3/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28890506 0.81 ALDH1A1 (0.45) MAPTKDM4EALDH1A1CASP1CASP7
SCHEMBL7823572 0.80 MAPT (0.50) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL5783701 0.77 ALDH1A1 (0.38) MAPTKDM4EALDH1A1CASP1CASP7
SCHEMBL5780859 0.76 ALDH1A1 (0.43) MAPTKDM4EALDH1A1CASP1CASP7
SCHEMBL5778651 0.75 NPSR1 (0.42) MAPTKDM4EALDH1A1CASP1CASP7
SCHEMBL5786451 0.74 CYP2C19 (0.40) MAPTKDM4EALDH1A1CASP1CASP7
SCHEMBL19852262 0.74 MAPT (0.63) MAPTKDM4EALDH1A1CASP1CASP7
SCHEMBL5781907 0.74 TDP2 (0.45) MAPTKDM4EALDH1A1CASP1CASP7
SCHEMBL29440764 0.73 KDM4E (0.40) MAPTKDM4EALDH1A1CASP1CASP7
SCHEMBL8759432 0.73 TSHR (0.49) MAPTKDM4EALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1436293-B1 POLYCYCLIC COMPOUNDS HAVING ANTI-TUMOR ACTIVITY HOFFMANN LA ROCHE (CH) 2006-02-01 EP disclosed
US-6946472-B2 Polycyclic compounds exhibiting anti-tumor activities HOFFMAN-LA ROCHE INC. (US) 2005-09-20 US disclosed
EP-1436293-A1 POLYCYCLIC COMPOUNDS HAVING ANTI-TUMOR ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2004-07-14 EP disclosed
US-6680326-B2 ANTITUMOR AGENTS; ANTICANCER AGENTS HOFFMANN-LA ROCHE INC. 2004-01-20 US disclosed
US-20030229098-A1 Polycyclic compounds exhibiting anti-tumor activities F.HOFFMANN-LA ROCHE AG (CH) 2003-12-11 US disclosed
WO-2003093265-A1 DIMERIC POLYCYCLIC COMPOUNDS FOR THE TREATMENT OF TUMORS F. HOFFMANN-LA ROCHE AG (CH) 2003-11-13 WO disclosed
US-20030073691-A1 Polycyclic compounds HOFFMANN-LA ROCHE INC. 2003-04-17 US disclosed
WO-2003031444-A1 POLYCYCLIC COMPOUNDS HAVING ANTI-TUMOR ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2003-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073691-A1 Polycyclic compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, PKD1 MAPT 4594/4885KDM4E 1718/4885ALDH1A1 1636/4885
US-20030229098-A1 Polycyclic compounds exhibiting anti-tumor activities RB1, CCNA1, ACIN1 MAPT 4854/4885KDM4E 1010/4885ALDH1A1 642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.